文献速递肿瘤 PET/CT神经核医学

[18F]SiTATE-PET/CT检测嗜铬细胞瘤和副神经节瘤:生化分泌、基因型与影像指标的对比

[18F]SiTATE-PET/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-30

这项回顾性研究纳入34例经组织学确诊的嗜铬细胞瘤/副神经节瘤(PPGL)患者,于2020年10月至2024年2月在慕尼黑大学医院接受[18F]SiTATE-PET/CT及激素实验室分析。基于患者的检出率为96.6%,MTV和TLU与嗜铬粒蛋白A及生化分泌呈中度相关。

要点

  • 基于患者的[18F]SiTATE-PET检出率为96.6%。
  • MTV和TLU与嗜铬粒蛋白A呈中度相关(r=0.570-0.608,p<0.005)。
  • 遗传性PPGL Cluster 1基因型较散发性PPGL显示更强的[18F]SiTATE摄取。

核心结论

  • 这是[18F]SiTATE-PET/CT在PPGL患者中的首次临床评估。
  • MTV和TLU与血清嗜铬粒蛋白A及尿液和血浆(去甲)变肾上腺素相关良好。
  • 在小队列限制下,结果提示TLU和MTV可作为监测PPGL疾病进展和分泌活动的SSTR影像生物标志物。

研究设计与样本

  • 回顾性研究纳入34例经组织学确诊的PPGL患者,于2020年10月至2024年2月在慕尼黑大学医院接受[18F]SiTATE-PET/CT,并在100天内完成激素实验室分析。
  • 分析影像参数包括SUVmax、SUVmean、代谢肿瘤体积(MTV)和总病灶摄取(TLU),并以肝脏背景归一化(SUVmaxr、SUVmeanr)。
  • 采用Mann-Whitney U检验比较生化亚型和基因型的放射性配体摄取,采用Spearman秩相关检验进行相关性分析。

主要发现

  • 基于患者的[18F]SiTATE-PET检出率为96.6%。
  • MTV和TLU与嗜铬粒蛋白A呈中度相关(r=0.570-0.608,p<0.005),与生化分泌呈中度相关(r=0.466-0.576,p<0.05)。
  • 遗传性PPGL Cluster 1基因型较散发性PPGL显示更强的[18F]SiTATE摄取(SUVmeanr:p=0.032;SUVmaxr:p=0.051)。
  • 与[⁶⁸Ga]Ga-DOTATOC-PET/CT的亚组比较显示摄取指标或肿瘤-背景比无显著差异。

局限性

  • 原文结论指出结果受小队列的限制(「Within the limits imposed by the small cohort」)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Somatostatin-receptor (SSTR)-targeting PET/CT is widely used for diagnosis and disease monitoring of pheochromocytoma / paraganglioma (PPGL). The aim of this study was to assess the potential of the novel SSTR-targeting tracer [18F]SiTATE in diagnosing PPGL by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type. METHODS: This retrospective study included 34 patients with histologically confirmed PPGL who underwent [18F]SiTATE-PET/CT at LMU University Hospital Munich between 10/2020 and 02/2024 as well as hormonal laboratory analysis within up to 100 days. Imaging parameters - standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion uptake (TLU) - were analyzed. Uptake was normalized to liver background (SUVmaxr, SUVmeanr). Radioligand uptake of biochemical subtypes and genotypes was compared with Mann-Whitney-U test. Correlation was tested using Spearman´s rank correlation test. RESULTS: The patient-based detection rate of [18F]SiTATE-PET was 96.6%. A moderate correlation was found between MTV and TLU with chromogranin A (r = 0.570-0.608, p < 0.005) and with biochemical secretion (r = 0.466-0.576, p < 0.05). Hereditary PPGL with Cluster 1 genotype showed stronger [18F]SiTATE uptake compared to sporadic PPGL (SUVmeanr: p = 0.032; SUVmaxr: p = 0.051). A subgroup comparison with [⁶⁸Ga]Ga-DOTATOC-PET/CT revealed no significant difference in uptake metrics or tumor-to-background ratios. CONCLUSION: This is the first clinical evaluation of [18F]SiTATE-PET/CT in patients with PPGL. MTV and TLU measured with [18F]SiTATE-PET/CT correlated well with the tumor marker chromogranin A in serum and with (nor)metanephrines in urine and plasma. Within the limits imposed by the small cohort, our results suggest that TLU and MTV in [18F]SiTATE-PET/CT could be used as SSTR imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Onkes M, Dahlmann P, Gesenhues A, et al. [18F]SiTATE-PET/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics. Eur J Nucl Med Mol Imaging. 2025. PMID: 40445313. doi:10.1007/s00259-025-07341-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。